Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 14Triple Negative Breast Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Recurrence 1Lymphedema 1Li-Fraumeni Syndrome 1Hamartoma Syndrome, Multiple 1Carcinoma, Ductal, Breast 1Breast Carcinoma In Situ 1Breast Cancer Invasive 1Breast Cancer Female 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

pembrolizumab 96Carboplatin 67Paclitaxel 56Cyclophosphamide 40Capecitabine 30Specimen Handling 28sacituzumab govitecan 25130-nm albumin-bound paclitaxel 24Gemcitabine 22Magnetic Resonance Spectroscopy 21Doxorubicin 20olaparib 19Taxes 19Biopsy 19Albumin-Bound Paclitaxel 19Drug Therapy 16atezolizumab 13Nivolumab 13toripalimab 12Radiotherapy 12Epirubicin 12durvalumab 11Docetaxel 10Cisplatin 10Bevacizumab 10eribulin 9fludarabine 8Standard of Care 7Radiation 7Injections 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Mastectomy × 1 year × Clear all
NCT02883062 2026-05-28

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
67 enrolled 16 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07217990 2026-02-17

NoCUT-BC

Ohio State University Comprehensive Cancer Center

Phase 1/2 Not yet recruiting
84 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡